UNSPSC 51391603: Amrinone or inamrinone

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C10H9N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JUT23379TN, chemically known as 5-amino-(3,4-bipyridin)-6(1h)-one but generally known as amrinone, which bears US NIH Compound Identifier 3698. European Medicines Agency schedules Amrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05493MIG.

UNSPSC 51391603 Amrinone or inamrinone is a Commodity code representing a specific pharmaceutical product class, but recent state and local procurement activity tagged under this code shows little relevance to the nominal scope. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking Naloxone and Safe Drug Deactivation Systems (1,900 units of Naloxone and 800 deactivation systems annually) through competitive sealed bidding with quarterly deliveries to the county's community health building. Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as an exploratory market-intelligence solicitation regarding direct-to-manufacturer prescription programs and vendor capabilities for implementing a Therapeutic Pharmacy Initiative, but this RFI does not specify amrinone or inamrinone procurement. The mismatch between the code's pharmaceutical specification and the actual work being solicited — Naloxone supply and pharmacy benefit program restructuring — suggests the code as currently indexed does not track meaningful state and local procurement volume in these categories.

Activity is sparse and geographically scattered. Seminole County's Naloxone procurement (IFB, response deadline July 26, 2023, with a fixed-fee two-year initial term plus one-year renewal option) represents direct pharmaceutical supply to a county health program, while the Texas HHS RFI (posted April 3, 2026, response deadline April 3, 2026) is a preliminary information-gathering mechanism rather than a formal solicitation and does not commit to specific products or volumes. State health authorities and county health departments appear to be the primary issuing bodies when the code does surface, but without additional recent opportunities tied to amrinone or inamrinone specifically, the code shows limited current procurement momentum for business development purposes.